X hits on this document

PDF document

Revised January, 2010 CONFIDENTIAL AND PROPRIETARY - page 3 / 31

76 views

0 shares

0 downloads

0 comments

3 / 31

CONFIDENTIAL AND PROPRIETARY

LTC Signature Logs................................................................................................... 19 LICS Status ............................................................................................................... 20 LTC Rebate Reporting............................................................................................... 20 Medicare Part D Vaccines............................................................................................. 20 Submitting claims POS (Point of Sale):......................................................................... 20 Pharmacy Audit Program .............................................................................................. 21 Overview.................................................................................................................... 21 Audit Notification .................................................................................................... 21 Signature Logs....................................................................................................... 22 Documentation Requirements................................................................................ 22 Dispensing Limits....................................................................................................... 23 Quantity.................................................................................................................. 23 Days Supply........................................................................................................... 23 Insulin..................................................................................................................... 23 Inhalers .................................................................................................................. 23 Ophthalmic Drops .................................................................................................. 23 U&C- Usual and Customary ...................................................................................... 23 DAW (dispense as written) Codes............................................................................. 23 Compounds............................................................................................................ 24 Reversals................................................................................................................... 24 Results and Appeals.................................................................................................. 25 MedMonitor® Complete ................................................................................................ 25 MedMonitor®24............................................................................................................. 25 Drug-Drug Interactions .............................................................................................. 26 Drug-Disease Interactions ......................................................................................... 26 Drug-Diagnosed Disease Interactions ....................................................................... 26 Therapeutic Appropriateness..................................................................................... 26 Overutilization or Duration of Therapy ....................................................................... 27 High Dose.................................................................................................................. 27 Underutilization .......................................................................................................... 27 Therapeutic Duplication............................................................................................. 27 MedMonitor®XR............................................................................................................ 27 Program Design and Components............................................................................. 28 Member Access to MTM Services ............................................................................. 29 Provider Participation and MTM Guide...................................................................... 30 Other Resources ........................................................................................................... 31 Web sites................................................................................................................... 31 General Email............................................................................................................ 31 Fraud, Waste and Abuse Contact Information........................................................... 31

Walgreens Health Initiatives – Pharmacy Manual

3

Document info
Document views76
Page views76
Page last viewedThu Dec 08 02:45:15 UTC 2016
Pages31
Paragraphs481
Words10035

Comments